{"preliminary_commentary":{"by_channel":{"x_thread":14,"youtube":5,"podcast":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT07566156\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"EV-309","nct_id":"NCT07566156","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ev-309-nct07566156. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Enfortumab vedotin + pembrolizumab (EV + P)","label":"Arm A","type":"EXPERIMENTAL"},{"description":"Concurrent Chemoradiotherapy (cCRT)","label":"Arm B","type":"ACTIVE_COMPARATOR"}],"collaborators":["Pfizer"],"completion_date":{"date":"2032-02-29","type":"ESTIMATED"},"conditions":["Urothelial Cancer","Urinary Bladder Neoplasms"],"enrollment":{"count":390,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Enfortumab vedotin","otherNames":["• Padcev","• ASG-22CE","• ASG-22Me"],"type":"DRUG"},{"name":"Conventional Radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"Hypofractionated Radiotherapy","otherNames":[],"type":"RADIATION"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Fluorouracil","otherNames":["• 5-Fluorouracil","• 5-FU"],"type":"DRUG"},{"name":"Mitomycin C","otherNames":["• MMC"],"type":"DRUG"},{"name":"Gemcitabine","otherNames":[],"type":"DRUG"},{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"}],"last_update":"2026-10-28","lead_sponsor":"Astellas Pharma Global Development, Inc.","official_title":"A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB IN ADULT PARTICIPANTS WITH MUSCLE-INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR OR HAVE ELECTED NOT TO UNDERGO CYSTECTOMY","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-03-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 45.5 months"},{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 60 months"}],"references":[],"start_date":{"date":"2026-05-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)","url":"https://clinicaltrials.gov/study/NCT07566156"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ev-309-nct07566156"}